Estée Lauder stock moved higher Friday as traders priced in improving sentiment around the company’s premium-skincare-led turnaround and positioned ahead of its fiscal 2026 third-quarter earnings window. The near-term catalyst in the news flow is the company’s April 29 announcement that it took a minority stake in luxury clinical skincare brand 111SKIN, a move seen as consistent with its strategy of leaning into higher-end, science-backed skincare where pricing power and brand storytelling can support margins.

The 111SKIN deal reinforces a portfolio “premiumization” narrative at a time when investors are particularly sensitive to signs that Estée Lauder can stabilize demand and rebuild profitability after a difficult stretch for prestige beauty in certain channels. The investment also gives the company a foothold in a fast-growing niche—clinical-luxury skincare—without the balance-sheet commitment of a full acquisition, while leaving room for deeper partnership or consolidation later if performance warrants.

Today’s gain also reflects the market’s broader focus on whether Estée Lauder can keep translating restructuring and cost actions into sustained margin expansion through fiscal 2026. The company previously raised its fiscal 2026 EPS outlook in its Feb. 5, 2026 quarterly update, and investors are looking for additional confirmation that operational improvements can persist even if demand remains choppy in key regions and channels.